Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:32:42.439Z.
Consensus retrieved: 2026-10-06T15:34:27.221Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:32:42.439Z.
Quote observation: 2026-10-06T18:29:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cae73e0f7d7453288b6b30bb28ae33caa2dcc4a3490ac3f0933bc7bc3ce0e433
Forward PE Ratio (N/A) = Dated Quote Price ($130.38) / Consensus Forward EPS ($-6.60)
FORWARD PE RATIO
N/A
Palvella Therapeutics, Inc.
Market Cap
$1.87B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.87B | N/A |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.89B | N/A |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.35 |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 26.65 |
| Azenta, Inc. (AZTA)vs › | $1.84B | 80.51 |
| Zymeworks Inc. (ZYME)vs › | $1.90B | 24.92 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | N/A |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | 5.37 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $130.38, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-6.60 | $-8.09 – $-4.08 | 11 | n/m |
| 2027-12-31 | $-7.98 | $-12.87 – $-3.45 | 9 | n/m |
| 2028-12-31 | $-5.77 | $-10.80 – $-0.78 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
